<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mepivacaine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mepivacaine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mepivacaine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11559" href="/d/html/11559.html" rel="external">see "Mepivacaine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13030" href="/d/html/13030.html" rel="external">see "Mepivacaine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192931"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carbocaine;</li>
<li>Carbocaine Preservative-Free;</li>
<li>Polocaine;</li>
<li>Polocaine Dental;</li>
<li>Polocaine-MPF;</li>
<li>Scandonest 3% Plain</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912150"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Carbocaine;</li>
<li>Polocaine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192962"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F192934"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Use the smallest dose and concentration required to produce the desired result. Dosage varies with anesthetic procedure, area to be anesthetized, vascularity of the tissues, number of neuronal segments to be blocked, depth of anesthesia and degree of muscle relaxation required, duration of anesthesia, and tolerance and physical condition of the patient. During epidural administration, a test dose (45 to 50 mg) is recommended prior to induction of complete block and all reinforcing doses with continuous catheter technique. The test dose should contain epinephrine to serve as a warning of unintended intravascular injection.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46dd0d85-641f-4236-9e10-1bfcf6c0833a">Local or regional anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local </b>
<b>or regional anesthesia (eg, epidural, caudal, or peripheral nerve blocks): Note: </b>
<i>Maximum daily dose</i>: 1,000 mg per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caudal and epidural block (preservative free solutions only):</i> 15 to 30 mL of a 1% solution (maximum total dose: 300 mg) <b>or</b> 10 to 25 mL of a 1.5% solution (maximum total dose: 375 mg) <b>or</b> 10 to 20 mL of a 2% solution (maximum total dose: 400 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cervical, brachial, intercostal, pudendal nerve block:</i> 5 to 40 mL of a 1% solution (maximum total dose: 400 mg) <b>or</b> 5 to 20 mL of a 2% solution (maximum total dose: 400 mg). For pudendal block, inject one-half the total dose to each side.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infiltration:</i> Up to 40 mL of a 1% solution (maximum total dose: 400 mg); up to 50 mL of a 1% solution if epinephrine has been added (maximum total dose: 500 mg) (Gropper 2020); an equivalent amount of a 0.5% solution (prepared by diluting the 1% solution with NS) may be used for large areas.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Paracervical block:</i> Up to 20 mL (total for both sides) of a 1% solution (maximum total dose: 200 mg). Inject one-half the total dose to each side. This is the maximum recommended dose per 90-minute procedure; inject slowly with 5 minutes between sides.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral nerve block to provide a surgical level of anesthesia (off-label):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Major nerve block (blockade of 2 or more distinct nerves, a nerve plexus, or very large nerves at more proximal sites): 30 to 50 mL of a 1% or 1.5% solution (maximum total dose: 350 mg; if epinephrine has been added, maximum total dose: 500 mg) (Gropper 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Minor nerve block (blockade of a single nerve [eg, ulnar or radial]): 5 to 20 mL of a 1% solution (maximum total dose: 200 mg) (Gropper 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Therapeutic block:</i> 1 to 5 mL of 1% solution (maximum total dose: 50 mg) <b>or</b> 1 to 5 mL of 2% solution (maximum total dose: 100 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transvaginal block (paracervical plus pudendal):</i> Up to 30 mL (total for both sides) of a 1% solution (maximum total dose: 300 mg). Inject one-half the total dose to each side.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Single site in upper or lower jaw: 51 mg as a 3% solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration and nerve block of entire oral cavity: 270 mg as a 3% solution. Maximum total dose: 400 mg.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Amount</b>
<b> of Mepivacaine (3%) Dental Anesthetic per Number of Dental Cartridges (1.7 mL)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Number </b> of cartridges</p>
<p style="text-indent:0em;">(1.7 mL)</p></th>
<th align="center">
<p style="text-indent:0em;">Mepivacaine mg</p>
<p style="text-indent:0em;">(3%)</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">1</p></td>
<td align="center">
<p style="text-indent:0em;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="center">
<p style="text-indent:0em;">102</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">153</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">204</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">255</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">306</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="center">
<p style="text-indent:0em;">357</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">408</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990138"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; consider a reduced dose (especially with repeated dosing) in patients with moderate to severe impairment.</p></div>
<div class="block doha drugH1Div" id="F50987456"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; consider a reduced dose (especially with repeated dosing) in patients with moderate to severe impairment.</p></div>
<div class="block doe drugH1Div" id="F192935"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; reduce dose consistent with age and physical status.</p></div>
<div class="block dop drugH1Div" id="F192949"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13030" href="/d/html/13030.html" rel="external">see "Mepivacaine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. The smallest dose and concentration required to produce the desired effect should be used. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia:</b> Children and Adolescents: 3% solution: Injection:</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Maximum dose: 5 to 6 mg/kg; maximum total dose: 270 mg. In adults, the dose for single site in upper or lower jaw is 51 mg (one 1.7 mL cartridge).</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate dosing: American Academy Pediatric Dentistry (AAPD 2015): Maximum dose: 4.4 mg/kg; maximum total dose: 300 mg in any single dental sitting.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46dd0d85-641f-4236-9e10-1bfcf6c0833a">Local or regional anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local or regional anesthesia (eg, epidural, caudal, or peripheral nerve blocks):</b> Maximum single or total dose given for one procedure: 5 to 6 mg/kg (maximum adult dose per manufacturer: 400 mg); only concentrations &lt;2% should be used in patients &lt;3 years or &lt;14 kg to ensure adequate drug volume for area and to decrease the potential for local anesthetic systemic toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129301"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51129302"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.</p></div>
<div class="block adr drugH1Div" id="F192909"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed may be based on reports for other agents in this same pharmacologic class and may not be specifically reported for mepivacaine.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac insufficiency, cardiovascular depression, cardiovascular stimulation, heart block, hypertension, hypotension, low cardiac output, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal incontinence, loss of anal sphincter control, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Sexual disorder (sexual function), urinary incontinence, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylactic shock, anaphylaxis, angioedema, and nonimmune anaphylaxis) (Estrada 2011; Nam 2023; Takahashi 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Septic meningitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, central nervous system depression, chills, confusion, cranial nerve palsy, dizziness, drowsiness, excitement, headache, loss of consciousness, meningism, paralysis, paresthesia, persistent anesthesia, restlessness, seizure, sensation disorder (loss of perineal sensation), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, miosis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, hypoventilation, respiratory depression, respiratory paralysis</p></div>
<div class="block coi drugH1Div" id="F192919"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to mepivacaine, other amide-type local anesthetics, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F192906"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Use extreme caution in patients with existing neurological disease. Seizures due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection. In the event of cardiovascular collapse and/or severe CNS toxicity, treatment in accordance with the American Society of Regional Anesthesia and Pain Medicine’s Checklist for Treatment of Local Anesthetic Toxicity is recommended (ASRA [Neal 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Familial malignant hyperthermia: Although product labeling suggests that mepivacaine may potentially trigger malignant hyperthermia, evidence and expert consensus do not support and use is considered to be safe (MHAUS 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest. Careful and constant monitoring of the patient's respiratory (adequacy of ventilation) vital signs should be done following each local anesthetic injection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including rhythm disturbances, hypotension/shock, and heart block; consider a reduced dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Because of the inability to metabolize local anesthetics, patients with severe hepatic disease are at a greater risk of developing toxic plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Preservative-containing solutions: Do not use solutions containing preservatives for caudal or epidural block.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate dosing: To avoid serious adverse effects and high plasma levels, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may cause significant increases in blood levels with each repeated dose due to the possibility of accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with patient status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Test dose: A test dose is recommended prior to epidural administration and all reinforcing doses with continuous catheter technique.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F192914"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbocaine: 1% (50 mL); 2% (50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Polocaine: 1% (50 mL); 2% (50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbocaine Preservative-Free: 1% (30 mL); 1.5% (30 mL); 2% (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Polocaine-MPF: 1% (30 mL); 1.5% (30 mL); 2% (20 mL) [methylparaben free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [dental use]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbocaine: 3% (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Polocaine Dental: 3% (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Scandonest 3% Plain: 3% (1.7 mL)</p></div>
<div class="block geq drugH1Div" id="F192902"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323371"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Polocaine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Polocaine-MPF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5% (per mL): $0.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F192916"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Not for intrathecal use. Intravascular or subarachnoid injections should be avoided. Have resuscitative equipment and medications readily available during administration. Administer slowly in small, incremental doses; avoid rapid injection of a large volume. Use an indwelling IV catheter during major regional nerve block (eg, brachial plexus, lower extremity). Aspirate for blood or cerebrospinal fluid (if applicable) before administration of all doses; absence of blood or cerebrospinal fluid in the syringe does not guarantee that intravascular or intrathecal injection has been avoided. Avoid puncturing the skin when there is inflammation and/or infection in the region of the proposed injection. Do not use injections containing preservatives (eg, methylparaben in multiple-dose vials) for epidural or caudal anesthesia.</p></div>
<div class="block admp drugH1Div" id="F52613257"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery. Administer slowly in small incremental doses, with frequent aspirations before and during the injection to avoid intravascular injection. Use with caution when there is inflammation and/or sepsis in the region of the proposed injection.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Dental: Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.</p></div>
<div class="block use drugH1Div" id="F192915"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia:</b> Production of local anesthesia for dental procedures by infiltration or nerve block in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Local or regional anesthesia</b>
<b>(eg, epidural, caudal, or peripheral nerve blocks):</b> Production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques (epidural and caudal) in adult and pediatric patients. <b>Not</b> for use in spinal anesthesia.</p></div>
<div class="block mst drugH1Div" id="F192969"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Mepivacaine may be confused with BUPivacaine</p>
<p style="text-indent:-2em;margin-left:4em;">Polocaine may be confused with prilocaine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299669"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221552"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May increase the serum concentration of Mepivacaine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2234302"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Mepivacaine has been used in obstetrical analgesia.</p></div>
<div class="block brc drugH1Div" id="F20616179"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if mepivacaine is present in breast milk. The manufacturer recommends that caution be exercised when administering mepivacaine to breastfeeding women. Usual infiltration doses of mepivacaine dental anesthetic given to breastfeeding mothers has not been shown to affect the health of the breastfeeding infant.</p></div>
<div class="block mop drugH1Div" id="F2234306"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiovascular and respiratory status; vital signs (eg, BP, heart rate, oxygen saturation); mental status changes; signs of CNS toxicity (eg, seizures, visual changes, muscle twitching); systemic toxicity, especially in patients with moderate to severe hepatic or kidney impairment.</p></div>
<div class="block pha drugH1Div" id="F192905"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mepivacaine is an amide local anesthetic similar to lidocaine. Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns. </p></div>
<div class="block phk drugH1Div" id="F192918"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action (route and dose dependent): Range: 3 to 20 minutes; Dental: Upper jaw: 30 to 120 seconds; Lower jaw: 1 to 4 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration (route and dose dependent): 2 to 2.5 hours; Dental: Upper jaw: 20 minutes; Lower jaw: 40 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~75%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via N-demethylation, hydroxylation, and glucuronidation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Neonates: 8.7 to 9 hours; Adults: 1.9 to 3.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (90% to 95% as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58843719"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Isocaine | Scandinibsa | Scandonest</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAPD.1">
<a name="AAPD.1"></a>American Association of Pediatric Dentists (AAPD), Council on Clinical Affairs. Guideline on use of local anesthesia for pediatric dental patients. Revised 2015. http://www.aapd.org/media/Policies_Guidelines/G_LocalAnesthesia.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1397990">
<a name="1397990"></a>Ayoub ST and Coleman AE. A review of local anesthetics. <i>Gen Dent.</i> 1992;40(4):285-287, 289-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/1397990/pubmed" id="1397990" target="_blank">1397990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbocaine.2">
<a name="Carbocaine.2"></a>Carbocaine 3% injection (mepivacaine hydrochloride) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canada Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbocaine.1">
<a name="Carbocaine.1"></a>Carbocaine 1%, 1.5%, and 2% injection (mepivacaine hydrochloride) [prescribing information]. Lake Forest, IL: Hospira Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cousins.1">
<a name="Cousins.1"></a>Cousins MJ. Neural blockade. In: <i>Clinical Anesthesia and Pain Medicine</i>. 4th ed. Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al. Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion. <i>Crit Care Med</i>. 2011;39(4):872-874.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21995186">
<a name="21995186"></a>Estrada JL, Perez-Laiz JL, Latasa M, Rodríguez-Paredes A. Immediate allergy to mepivacaine. <i>J Investig Allergol Clin Immunol</i>. 2011;21(6):492-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/21995186/pubmed" id="21995186" target="_blank">21995186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19840499">
<a name="19840499"></a>Gaffen AS and Haas DA. Retrospective review of voluntary reports of nonsurgical paresthesia in dentistry. <i>J Can Dent Assoc.</i> 2009;75(8):579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/19840499/pubmed" id="19840499" target="_blank">19840499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20592403">
<a name="20592403"></a>Garisto GA, Gaffen AS, Lawrence HP, et al. Occurrence of paresthesia after dental local anesthetic administration in the United States. <i>J Am Dent Assoc.</i> 2010;141(7):836-844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/20592403/pubmed" id="20592403" target="_blank">20592403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K, eds. <i>Miller’s Anesthesia</i>. 9th ed. Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17448066">
<a name="17448066"></a>Foxall G, McCahon R, Lamb J, et al. Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid. <i>Anaesthesia</i>. 2007;62(5):516-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/17448066/pubmed" id="17448066" target="_blank">17448066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16867094">
<a name="16867094"></a>Litz RJ, Popp M, Stehr SN, et al. Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion. <i>Anaesthesia</i>. 2006;61(8):800-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/16867094/pubmed" id="16867094" target="_blank">16867094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MHAUS.1">
<a name="MHAUS.1"></a>Malignant Hyperthermia Association of the United States (MHAUS). Safe and unsafe anesthetics. https://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics/. Accessed May 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20332339">
<a name="20332339"></a>Mirtallo JM, Dasta JF, Kleinschmidt KC, et al. State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications. <i>Ann Pharmacother</i>. 2010;44(4):688-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/20332339/pubmed" id="20332339" target="_blank">20332339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831923">
<a name="20831923"></a>Moore PA, Hersh EV. Local Anesthetics: Pharmacology and Toxicity. <i>Dent Clin North Am</i>. 2010;54(4):587-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/20831923/pubmed" id="20831923" target="_blank">20831923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20216035">
<a name="20216035"></a>Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/20216035/pubmed" id="20216035" target="_blank">20216035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37313269">
<a name="37313269"></a>Nam Y, Min S, Park W, Kim KD. Allergic reactions to local anesthetic mepivacaine in dental procedures: a case report. <i>J Dent Anesth Pain Med</i>. 2023;23(3):173-177. doi:10.17245/jdapm.2023.23.3.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/37313269/pubmed" id="37313269" target="_blank">37313269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22189574">
<a name="22189574"></a>Neal JM, Mulroy MF, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version. <i>Reg Anesth Pain Med</i>. 2012;37(1):16-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/22189574/pubmed" id="22189574" target="_blank">22189574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33148630">
<a name="33148630"></a>Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version. <i>Reg Anesth Pain Med.</i> 2021;46(1):81-82. doi:10.1136/rapm-2020-101986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/33148630/pubmed" id="33148630" target="_blank">33148630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polocaine.3">
<a name="Polocaine.3"></a>Polocaine and Polocaine-MPF 1%, 1.5%, and 2% injection (mepivacaine hydrochloride) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polocaine.2">
<a name="Polocaine.2"></a>Polocaine Dental 3% (mepivacaine hydrochloride) and Polocaine Dental 2% with Levonordefrin (mepivacaine hydrochloride and levonordefrin) [prescribing information]. York, PA: Dentsply Pharmaceutical; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polocaine.1">
<a name="Polocaine.1"></a>Polocaine Dental 3% injection (mepivacaine hydrochloride) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canada Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16810015">
<a name="16810015"></a>Rosenblatt MA, Abel M, Fischer GW, et al. Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest. <i>Anesthesiology</i>. 2006;105(1):217-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/16810015/pubmed" id="16810015" target="_blank">16810015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ScandonestPlain.1">
<a name="ScandonestPlain.1"></a>Scandonest Plain (mepivacaine hydrochloride) [prescribing information]. Lancaster, PA: Septodont Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32026066">
<a name="32026066"></a>Takahashi M, Hotta K, Inoue S, et al. Mepivacaine-induced anaphylactic shock in a pregnant woman undergoing combined spinal and epidural anesthesia for cesarean delivery: a case report. <i>JA Clin Rep</i>. 2019;5(1):84. doi:10.1186/s40981-019-0302-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/32026066/pubmed" id="32026066" target="_blank">32026066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7622755">
<a name="7622755"></a>Torres MJ, Garcia JJ, del Cano Moratinos AM, et al. Fixed Drug Eruption Induced by Mepivacaine. <i>J Allergy Clin Immunol</i>. 1995;96(1):130-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/7622755/pubmed" id="7622755" target="_blank">7622755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8940589">
<a name="8940589"></a>Wynn RL. Recent research on mechanisms of local anesthetics. <i>Gen Dent.</i> 1995;43(4):316-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mepivacaine-drug-information/abstract-text/8940589/pubmed" id="8940589" target="_blank">8940589</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9610 Version 181.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
